Aurobindo gets approval for Sumatriptan Succinate tabs

RELATED NEWS Aurobindo Pharma Q3 PAT at Rs 55.25 cr Aurobindo Pharma’s total income Rs 549.42cr Q3 result analysis: Bajaj Hind, Aurobindo Ph, LT Overseas ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 10/02/12 Are Mutual Funds betting on Aurobindo Pharm? Other Stocks in this news GlaxoSmithKline Pharmaceuticals |

Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US Food & Drug Administration to manufacture and market Sumatriptan Succinate Tablets 25mg, 50mg and 100mg.

 

Sumatriptan Succinate Tablets are the generic equivalent of GlaxoSmithKline 's Imitrex® Tablets, which are indicated for the treatment of acute migraine headaches.

 

Annual sales of Sumatriptan Succinate Tablets 25mg, 50mg and 100m. in the US were approximately US$ 950 million for the twelve months ending MAT/3/2007 according to IMS Health data

 

This is Aurobindo's 63rd ANDA approval from the USFDA 

 

Sourced From: Aurobindo Pharma Limited